fda ind, page-36

Cool, if was running BLT I would not make any announcement about results until such time as I had sorted out how the company is going to find the capital necessary to progress TT-034 to the next stage. The company will have a clear indication of the safety of TT-034 within weeks of the first cohort being dosed but there will be no compulsion to publish these results. Efficacy will take a while longer, however, early, unannounced indicators should be sufficient to get a deal done or secure support for an IPO for Tacere.

When one these two ways forward had been taken as for as it could be without shareholder approval, I would make one announcement that covered both bits of news. This would not contravene ASX rules as the only time the clinical trial is supposed to report is at its conclusion - anything else is a bonus.

Doing things this way would ensure the maximum sp result and would sustain the sp beyond a P&D. If management adopt this approach then we may have to wait until closer to the end of the year before we hear any more news.